POPULARITY
35 episodes with sld
11 episodes with sld
7 episodes with sld
12 episodes with sld
11 episodes with sld
6 episodes with sld
5 episodes with sld
5 episodes with sld
6 episodes with sld
Tymczasem rzutem na taśmę, tuż przed ciszą wyborczą, zapraszamy na drugi odcinek prezydencki Podkastu Dezinformacyjnego. Dowiecie się z niego dlaczego Maciej Maciak może i jest śmieszny i smutny, ale przecież Braun też tak wyglądał dekadę temu. Dowiecie się, że Marek Jakubiak prawdopodobnie kupował sobie podpisy, a gość, który mu to robił, jest dzisiaj w sztabie kandydata Bartoszewicza, który też przyszedł znikąd i nagle miał podpisy. Dowiecie się także co Bartoszewicz mówi o wojnie w Ukrainie i dlaczego nie warto się nabierać na “antysystemowość” takich kandydatów. I dlaczego trzeba ostrożnie z memiczną Joanną Senyszyn, której niektórzy z Was mogą nie pamiętać z czasów starego SLD.Dywagujemy sobie także na temat roli Krzysztofa Stanowskiego i Brauna. A także pozwalamy sobie liczyć (hehe) razem poparcie Magdy Biejat i Adriana Zandberga, które w kolejnych sondażach przekracza 10% - wynik niewidziany na lewicy od 15 lat. Zastanawiamy się ile w tym dobrej kampanii, a ile prawicowego skrętu Rafała Trzaskowskiego. Pytamy także “po co i dlaczego” Szymon Hołownia w ogóle bierze udział w tym wyścigu. Więcej czasu poświęcamy oczywiście górnym trzem kandydatom. Ku naszej uldze, Sławek zaliczył spektakularny zjazd z sondażowych szczytów w marcu. Wśród powodów był prawdopodobnie ten, że światło dzienne ujrzał doradca ds. wojskowych Sławka - niejaki Jacek Hoga. Zaimportowany od Brauna radykał, który żali się, że w Polsce nie ma oficjalnego stronnictwa rosyjskiego. Z kolei Tadeusz Batyr ewidentnie nie sprawdził się w swojej roli z powodów, że tak powiem, osobistych. Okazało się bowiem, że robienie kampanii na rozpisce treningowej, zawłaszczaniu mieszkań starszych ludzi oraz znajomości z neonazistami - gwarantuje wynik nawet niższy niż sondażowe poparcie dla macierzystej partii. Wreszcie ze smutkiem konstatujemy, że Rafał Trzaskowski właściwie nie musiał nic robić (i nie robił), a i tak pewnie wygra. Ba, Rafał mocno starał się zniechęcić do siebie całe grupy “naturalnego” dla niego elektoratu, co być może zaowocowało wzrostem Biejat i Zandberga.Wyszło z tego ponad dwie godziny. Zapraszamy!Zachęcamy do wspierania nas na Patronite:https://patronite.pl/Podkast_Dezinformacyjny
his conversation is the concluding segment of SurfingMASH's coverage of the AASLD Emerging Trends Conference on the SLD Spectrum diseases: MASLD, MetALD and ALD. In addition to co-hosts Louise Campbell and Roger Green, panelists include EASL Secretary General Aleksander Krag, hepatologist Alex Lalos and Jenn Leigh Jones, Founder of the Society for Sober Livers Survival patient advocacy group.The conversation starts with Roger questioning whether it is a good or bad idea to conduct separate studies on medicines' effect on MetALD patients. He notes Anna Marie Diehl's presentation at the Conference, which suggested that regardless of organ, all cell senescence and death results from iron overload, and asks whether we should be studying this phenomenon. Aleksander agrees that important questions around iron exist and should be addressed in future research. He places this issue in context by noting that after decades of failed drug trials, SLD research has produced a string of exciting successes using different modes of action. The group turns to discuss cirrhosis, based on recent presentations from Akero Therapeutics for its agent efruxifermin. Alex notes that his quick read of slides revealed that some of the cirrhosis patients had fairly advanced disease. He expresses a high level of enthusiasm that the prospective MASLD therapies discussed in this meeting will be the third major advance during his career in medicine.Roger asks the group two closing questions: one lesson each panelist is taking from the meeting and one message they would like to share with listeners. The group members all land in a similar place: there is a spectrum running from MASLD through MetALD to ALD and we are learning how their commonalities and differences are the keys to developing better treatments and guidelines.
00:00:00 - Surf's Up: Season 6 Episode 4 Surfing the MASH Tsunami concludes its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on pivotal messages that attendees took away from the conference and what messages they would like to share with listeners. Our newsmaker, Fatty Liver Alliance and CEO Mike Betel, discusses the lessons he has taken from being invited to a far wider swath of conferences this year and shares the messages he delivers to these new audiences. Finally, our expert, hepatology research and key opinion leader Mazen Noureddin, discusses recent advances in drug development, focusing on agents in Phase 3 trials.00:04:24 - IntroductionHost Roger Green briefly describes this episode's three sections and one key lesson from each.00:06:03 - Roundtable: Highlights from the AASLD Emerging Trends Conference, Part 4This is the concluding portion of our Emerging Trends Conference Roundtable. The group focuses on key lessons they have learned and messages they would like listeners to take from this conversation. The pivotal idea is that SLD is a spectrum running from MASLD through MetALD to ALD. Researchers and treaters will all do best in developing and implementing therapies and guidelines with this thought in mind. Aleksander Krag stresses this idea and notes that, with several different classes of drugs demonstrating positive impact, it will be an exciting decade ahead as we learn how to apply these drugs along the spectrum. Jenn Jones and Alex Lalos note the importance of identifying MetALD, although Jenn noted that it does not seem wise to conduct trials solely with MetALD patients at this time. 00:22:04 - Newsmaker: Mike Betel on the Increased Visibility of Patient AdvocatesThis week's newsmaker, Mike Betel, has experienced a significant increase in the number of conferences at which he is invited to speak or appear on a panel. This discussion centers around the reasons Mike believes this is happening and the message(s) he delivers. To Mike, his most important contribution lies in the amount of information he sends back from each event, many of which surpass 30% download rates (and some even hit 50%). He discusses his value in diabetes, endocrinology and obesity meetings, where he brings a "liver" perspective and co-education opportunity to these events. The entire experience has taught him about the need not to stigmatize patients and reinforced his belief in the importance of tailoring care to patients' needs and personalities. 00:49:28 - Expert: Mazen Noureddin on the Exciting MASLD Drug Development EnvironmentHepatologist and Key Opinion Leader Mazen Noureddin joins Roger to discuss major advances in drug development over the past year. He covers a range of different drug classes, focusing on stages of development and the range of options within each class. Specifically, he discusses the FGF-21 agents, the range of patients for whom they might be appropriate, how efruxifermin's 96-week results may make the idea of "induction therapy" less appropriate, and the exciting early data on cirrhosis patients. He provides some detail on the various incretin agonist options, why hepatologists are particularly excited about combinations that include a glucagon agent, and what kinds of results we might expect in upcoming trials. He goes on to discuss the pan-PPAR lanifibranor, the FASN inhibitor denifenstat, and notes ongoing work on new classes and combination therapies. In general, he paints, I think, not a rosy, but an extremely optimistic picture of what the future will be for patients who need to be treated for fatty liver. 01:09:38 - Business Report Roger discusses the next Roundtable and provides some details on SurfingMASH's coverage of the upcoming EASL Congress.
- SLD to czas przeszły, ponieważ Włodzimierz Czarzasty go zlikwidował. To są ludzie bezideowi. Gdy w sposób skandaliczny doszło do obniżenia składki zdrowotnej dla przedsiębiorców, powinni wyjść z koalicji, co nie oznacza, że nie powinna popierać wszystkich ustaleń koalicyjnych. Bardziej cenią stołki niż idee - mówi kandydatka na prezydenta Joanna Senyszyn.Gościem programu Jacka Nizinkiewicza #RZECZoPOLITYCE była Prof. Joanna Senyszyn, kandydatka na urząd prezydenta RP, ekonomistka, była posłanka SLD.Kup subskrypcję „Rzeczpospolitej” pod adresem: https://czytaj.rp.plWięcej na stronie: https://www.rp.plX: https://x.com/rzeczpospolitaFacebooku: https://www.facebook.com/dziennikrzeczpospolitaLinkedin: https://www.linkedin.com/company/rzeczpospolita
This week's Expert is Jeff McIntyre, Vice President, Liver Programs at the Global Liver Institute. His major topic is how recent high-level FDA job cuts might affect MASH drug and diagnostics development. He also shares reactions to FibroSIGHT, HistoIndex's new digital pathology service for clinical practice. Highlight: Recent job cuts at the FDA will produce chaos in government and slow response to any emerging crises.Second Highlight: Patient self-advocacy becomes even more important in this environment.The conversation takes place on April 1, which lends context to Jeff's opening comment about the rate and nature of change in Washington, DC. He and Roger quickly focus on high-level job cuts at the FDA. Jeff believes that the clearest outcome from these changes is that the government will be less able to respond promptly and in a medically appropriate manner to future health crises. Jeff agrees with former FDA Commissioner Rob Califf's comment that the FDA as we know it "is dead," and that we have little idea what the future holds. A slower-moving, more chaotic government with a Secretary of HHS who minimizes pharmacotherapies for alternative therapies presents a challenge for all SLD patients. Jeff states that patients need to become more vigilant self-advocates (even more than they are today). He also identifies patient advocacy organizations like GLI as a place patients can go to seek the guidance and support they need from patient advocates. Finally, the conversation turns to discuss FibroSIGHT. Jeff describes FibroSIGHT as "exactly where we should be and should not be at the same time," a technology that takes a significant step forward in understanding and patient support, but one that ties us to biopsy as a standard for clinical care. Jeff and Roger agree this issue will play out over the coming years.
00:00:00 - Surf's Up: Season 6 Episode 2Surfing the MASH Tsunami continues its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on disease epidemiology and what it can teach us about the relative importance of alcohol and diet on disease progression. Our newsmaker, hepatology KOL and frequent Surfer Hannes Hagstrom, discusses what a recent paper demonstrates about the impact of MASLD on 15-year mortality and cause of death and how this information can improve patient care. Finally, our Expert, Shelbyville, Indiana internist Emily Ann Andeya, discusses her path from practicing internal medicine to focus on liver health (HINT: the common theme is insulin resistance).00:04:40 - IntroductionHost Roger Green briefly describes this episode's three sections and one key lesson from each.00:05:49 - Roundtable: Highlights from the AASLD Emerging Trends Conference, Part 2 The second portion of our Roundtable focuses on relative impact of alcohol and diet on disease progression and overall mortality and morbidity. It starts with Aleksander Krag sharing the highlights of his epidemiology presentation at the Emerging Trends Conference. Dr. Krag points out that while the vast majority of SLD patient live with MASLD, the vast majority of hospitalized patients and those living with late-stage cirrhosis live with ALD. Similarly, for the average patient, living with MetALD is more lethal than living with MASLD. Aleksander points out another challenge in defining where a patient lives on the ALD -> MetALD -> MASLD spectrum: patients' level of alcohol consumption is likely to change over time and many ALD or MetALD cirrhosis patients stop drinking altogether. The rest of this section considers the importance of stigma in correctly classifying patients and why genetics may become key to a message that minimizes patient stigma.00:25:50 - Newsmaker: Hepatology Researcher and KOL Hannes Hagstrom of the Karolinska Institute joins Roger to discuss cause-specific mortality in Swedish MASLD patientsOn March 24, the Journal of Hepatology posted a paper titled Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden. Co-author Hannes Hagstrom joins Roger to discuss the paper's key findings and implications for care. The key finding: living with MASLD leads to a significant increase in 15-year mortality. The most frequent cause of death among MASLD patients is cardiovascular disease, but the greatest increases in relative risk were due to HCC (HR ~ 35) and extra-hepatic cancers (HR ~ 26). Hannes points out that these results can serve as the beginning of a process where physicians can compute the risk at which individual patients place themselves through diet or alcohol patterns, which can aid patient understanding of the disease.00:44:22 - Experts: Internist Emily Ann Andeya discusses how she developed the commitment to treating liver disease that made her a "unicorn" in the words of one AASLD panelist and also brought her to attend the Emerging Trends Conference last monthRoger first met Emily Ann Andeya when she asked a question at a session of last fall's The Liver Meeting, and again at the Emerging Trends Conference, where Emily and her colleagues were likely the only primary care physicians in the room. Emily describes the path by which she went from wanting to be a cardiologist during medical school in the Philippines through years of nursing in the US to primary care practice and, how, focus on the liver as a key to overall metabolic health. Listen as Emily explains the importance of understanding insulin resistance in her transition, and how her vision affects the way she and her colleagues practice, the goals they set, and the exceptional levels of care they achieve.01:08:56 Business Report
00:00:00 - Surf's Up! Season 6 Episode 1SurfingMASH kicks off our sixth season in our new format, with three major elements to each episode. This week's Roundtable and Newsmakers segments focused on two recent conferences that took a multispecialty perspective on the range of medical and psychological issues affecting steatotic liver disease (a new concept specialty: steatology.") Our Expert this week is our co-host Jörn Schattenberg, discussing the educational and conceptual challenges of readying Europe for the EMA approval of resmetirom later this year.00:03:58 - Introductions and GroundbreakersHost Roger Green describes the new v2.0 format. He introduces the guests for this month's Roundtable discussion of the AASLD Emerging Trends conference: co-host Louise Campbell, hepatology KOL and EASL Secretary-General Aleksander Krag, Alcohol Use Disorder and Alcohol Liver Disease patient advocate and Sober Livers patient support organization co-founder Jenn Leigh Jones, and clinical hepatology Alexander Lalos. 00:15:46 - Roundtable: Highlights from the AASLD Emerging Trends Conference, Part 1The first portion of our Roundtable focuses on the emerging recognition throughout hepatology that MASLD, MetALD and ALD are best described as a disease spectrum, rather than discreet diseases. This has implications for the medical specialties involved in treatment and the entire way we look at this diseases.00:32:35 - Newsmakers: Arizona Liver Health Institute Chief Medical Officer Naim Alkhouri and Fatty Liver Alliance Founder Mike Betel Discuss the 2025 Deser Liver ConferenceNow in its fourth year, the Arizona Liver Health Institute's Desert Liver Conference has become a major multispecialty event on the Winter conference agenda. Arizona Liver Health Chief Medical Officer and hepatology KOL Naim Akhouri and patient advocate and Fatty Liver Alliance Founder Mike Betel join Roger Green to discuss the conference, including what makes it unique. Listen to Naim introduce a new description of the science of SLD.00:55:21 - Experts: SurfingMASH co-host and hepatology KOL Jörn Schattenberg joins Roger Green to discuss how Europe is preparing for the launch of resmetirom and his own focus on this issueOur third co-host, Jörn Schattenberg, could not join the February roundtable discussion. Here, he joins Roger to update listeners on his activities over the past six months. Most of the discussion centers around the necessary steps for Europe to prepare for the launch of resmetirom (anticipated to occur later this year), particularly given that the overall environment is more "siloed."01:11;15 - Wrap-up: Roger presents "the shortest Business Report ever"Roger discusses one continuing feature of Business Reports in the future from today and leaves all his other topics for next week.
„Oceniam, że poparcie dla Sławomira Mentzena będzie jeszcze rosło, bo politycy Konfederacji czerpią z tych samych strategii, które doprowadziły do władzy Donalda Trumpa” – mówi w podcaście „Rzecz w tym” Krzysztof Janik, były przewodniczący SLD.Kup subskrypcję „Rzeczpospolitej” pod adresem: czytaj.rp.pl
Vivid Photonics, a spin-out company from Tyndall National Institute based at University College Cork, has developed a breakthrough technology poised to revolutionise image quality in augmented and virtual reality (AR/VR). The team has developed a Horizontal Cavity Surface Emitting Super Luminescent Diode (SLD) technology - the first of its kind globally. This revolutionary light source technology is designed to deliver superior image quality in compact, ultra low-power, lightweight AR devices, such as smart glasses, paving the way for seamless integration into everyday experiences. This innovation has the potential to impact the areas of education, medicine, environmental science, entertainment, and more. The team behind the spin-out company, including Brian Corbett, is part of IPIC, the Research Ireland Centre for Photonics, and has extensive experience in the industry. A prolific inventor and innovator, Corbett's research has fuelled several spin-out companies, including InfiniLED, which was subsequently bought by Meta in 2016. The company launched to a global audience at Photonics West in San Francisco last week. Chris Gorman, CEO of Vivid Photonics, said: "This is an exciting time to be involved in Photonics, and Ireland is at the forefront of this industry. Years of advanced research in Tyndall have produced breakthrough manufacturing processes that will revolutionise how we generate projected light for small, lightweight AR glasses. The image quality this will achieve is anticipated to be on par with real life." Professor Paul Townsend, Director of IPIC and Head of Photonics, Tyndall, said, "I am excited to see the commercialisation of this latest innovation from Brian Corbett's world-leading photonics research group. This is a fantastic example of how investment in cutting-edge photonics research through programmes such as IPIC can generate impact". Professor William Scanlon, CEO, Tyndall said: "Vivid Photonics' technology is set to redefine how the digital and physical worlds interact. This spin-out company is testament to Tyndall's research excellence in the field of Photonics and we look forward to seeing the profound impact this tech will have across many different applications." Dr Sally Cudmore, Director of UCC Innovation, said: "It is great to see many years of Tyndall and UCC research come to fruition through the creation of a photonics spin-out company. The UCC Innovation team supported the project from conception to spin-out, and I would like to congratulate the research team on their entrepreneurial journey. Vivid Photonics will continue to develop Tyndall's SLD technology into products that will generate economic and social impact." More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upcoming Podcast email us at Simon@IrishTechNews.ie now to discuss. Irish Tech News have a range of services available to help promote your business. Why not drop us a line at Info@IrishTechNews.ie now to find out more about how we can help you reach our audience. You can also find and follow us on Twitter, LinkedIn, Facebook, Instagram, TikTok and Snapchat.
Esportmaniacos 2221: En el programa de hoy hemos contado con Miniduke para hablar de lo que ocurrió ayer en Superliga Domino's, además de pregunarle por el fenómeno que ha supuesto VVV este año para la ERL española. Por otro lado, hemos hablado del enfrentamiento que tendrá lugar mañana en Corea entre Zeus y su ex equipo, T1. Finalmente, hemos hecho nuestra tierlist de ADCs de LEC APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Duyufilit 00:13:01 - Momento minuter 00:20:50 - Repaso de SLD con Miniduke 01:06:40 - Zeus vs T1 en la LCK 01:11:50 - ¿Qué meta veremos en playoffs de LEC? 01:31:28 - Tierlist de ADCs
Esportmaníacos 2217: Arrancamos con el repaso a la vuelta de la LCK que empieza su segunda fase en este split de invierno. Seguimos con la vuelta de la Superliga Domino's que esta tarde empieza su fase Suizo repasando todos los enfrentamientos de la primera ronda. Finalmente, pasamos al debate sobre la retransmisión de las scrims, y rematamos con un tierlist de los top laners de la LEC tras la fase regular. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Duyufilit 00:16:30 - Segunda fase LCK Winter Split 00:29:35 - El Suizo de SLD empieza hoy 01:05:25 - Scrims en abierto entre FLY y C9 01:21:00 - Nuestros favoritos para ir al First Stand 01:31:00 - Filtraciones futuros juegos Riot Games 01:39:00 - Tierlist tops LEC Winter Split
Join us for the season premiere of EASL Studio Season 8 as we unpack key insights from the Steatotic Liver Disease (SLD) Summit. Explore the evolving consensus on patient trajectories, advancements in ALD and MetALD treatment pathways, and the latest endpoint discussions. The episode also highlights a holistic approach to diagnosing and managing comorbidities and revisits the standard of care in light of breakthroughs in MASH treatments.Moderator: Aleksander KragFaculty: Cyrielle Caussy, Sven Francque and Brian LeeThis EASL Studio is supported by Madrigal. EASL has received no input from Madrigal with regards to the content of this programme.Related episodesS7E3 – The changing face of Steatotic Liver Disease: Navigating new opportunities and emerging challengesEASL Studio at the Congress 2024: SLD nomenclature: Need for refinement?EASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscapeEASL Studio from EASL Congress 2023 – Steatotic liver disease global consensus to change nomenclatureAll EASL Studio Podcasts are available on EASL Campus.
What if the secret to parenting an ADHD child isn't trying harder—but trying differently?It makes sense when you think about it.ADHD brains are wired differently, and so are their challenges. ADHD coach Sharon Collon shares her journey from chaos to calm and how you can tailor solutions to your family's unique needs.After spending over $30,000 in her son's first year post-diagnosis and developing an autoimmune condition from burnout, Sharon discovered that success comes not from trying harder, but from trying *differently*.In this episode of Tell The Others, Heidi and Sharon dive deep into the surprising strategies that work for ADHD families while avoiding shame and overwhelm.Transform your approach to daily life with systems designed for ADHD brains.Discover why traditional parenting advice fails ADHD families and what actually works.Uncover the real reasons behind ADHD behaviors and how to address them.Timecodes00:00 - Introducing Sharon Collon.01:33 - Sharon's ADHD origin story.07:54 - The gift of lived experience.17:05 - What is ADHD coaching?25:17 - One-handed systems.38:44 - Working with your brain.41:50 - Five ADHD parenting tips.52:37 - Connection over correction.1:04:54 - Limiting beliefs about ADHD.1:11:05 - How to take action.About SharonSharon is an award winning, credentialed ADHD Coach, Consultant & Parent Expert (who is families trained). She is passionate about helping people with ADHD understand how their brain works and creating joyful, functional lives with ADHD. She loves anything that makes life easier with ADHD!Her husband and her three sons all have ADHD (throw in some Tourettes, ODD, OCD, SPD and SLD too). As well as Sharon's lived experience, she has been researching ADHD for over 15 years, studied at ADDCA in New York and the International Coaching Federation.Sharon has runs on the board, assisting over 35,000 families since The Functional Family was created. Sharon has won multiple awards including Business Awards - Outstanding Education Service, AusMumpreneur - Disabled Business Excellence, People's Choice Leadership, People's Choice Making a Difference and the Cook's Community Award.Learn more about Sharon's membership, ADHD & Families Program, and free resources -> https://www.thefunctionalfamily.com/work-with-me--Jalapeño or five-alarm fire? Take the quiz to learn your child's SPICY score and get a free, in-depth report with strategies to meet their unique needs
Zapoznaj się z trendami rynkowymi na 2025 rok według OANDA TMS Brokers: https://go.tms.pl/UkladOtwarty (0:00) Wstęp (1:36) Kim jest Marcin Giełzak? Lewicowe ugrupowania (9:00) Wpływ Aleksandra Kwaśniewskiego i Leszka Millera na Polskę i lewicę (13:06) Książka "Wieczna lewica" (17:10) Jak Marcin Giełzak zdał sobie sprawę czym jest lewica? (22:47) Działalność związkowa, biznes, działalność w partii Razem (28:44) Nienawiść z lewej strony (34:08) Trzeci stan, trzeci świat, trzecia droga, trzecia płeć – krótka historia lewicy (38:20) Czym powinna być dzisiaj lewica? (43:39) Czy Marcin Giełzak poszedłby walczyć? Trzeba umierać za ojczyznę? (54:00) Jak blisko jest Marcinowi Giełzakowi do partii Razem, Krytyki Politycznej, SLD? (1:08:44) Marcinowi Giełzakowi bliżej do konserwatysty niż liberała? Gościem rozmowy jest Marcin Giełzak, Dwie Lewe Ręce, autor książki pt. "Wieczna lewica" Mecenasi programu: Novoferm: https://www.novoferm.pl/ Zamów książkę Igora Janke: https://patronite-sklep.pl/produkt/sila-polski-igor- janke/ https://patronite.pl/igorjanke ➡️ Zachęcam do dołączenia do grona patronów Układu Otwartego. Jako patron, otrzymasz dostęp do grupy dyskusyjnej na Discordzie i specjalnych materiałów dla Patronów, a także newslettera z najciekawszymi artykułami z całego tygodnia. Układ Otwarty tworzy społeczność, w której możesz dzielić się swoimi myślami i pomysłami z osobami o podobnych zainteresowaniach. Państwa wsparcie pomoże kanałowi się rozwijać i tworzyć jeszcze lepsze treści. Układ Otwarty nagrywamy w https://bliskostudio.pl
- Kwaśniewski w inteligentny sposób lawirował pomiędzy środowiskami politycznymi. Było oczywiste, że jest bliższy SLD, oficjalnie popierał tę formację, ale jednocześnie nie był prezydentem na zawołanie obozu politycznego, potrafił wetować ustawy, był gotów pośredniczyć w negocjacjach np. przy wielkiej reformie samorządowej - mówił w Polskim Radiu 24 Michał Sutowski (Krytyka Polityczna).
W pierwszej części Expressu Biedrzyckiej z 28 listopada gościem jest wicemarszałek Sejmu Krzysztof Bosak z Konfederacji, z którym rozmawia Kamila Biedrzycka. Posłuchaj całej dyskusji!Oglądaj Express Biedrzyckiej na żywo w serwisie YouTube.Więcej informacji o programie na stronie Super Expressu.
W drugiej części Expressu Biedrzyckiej z 28 listopada gościem jest politolog Adam Traczyk, z którym rozmawia Kamila Biedrzycka. Posłuchaj całej dyskusji!Oglądaj Express Biedrzyckiej na żywo w serwisie YouTube.Więcej informacji o programie na stronie Super Expressu.
In this week's episode of the Empower LEP Podcast, host Jana Parker welcomes Dr. Ed Schultz, the brilliant and enthusiastic mind behind the Core Selective Evaluation Process (C-SEP). Dr. Schultz is passionate about revolutionizing how we identify Specific Learning Disabilities (SLD) by cutting through outdated, complex testing methods and focusing on what truly matters. As a professor of special education, trainer, and consultant, Dr. Schultz brings a wealth of knowledge on making evaluations more efficient and meaningful for students and educators alike.You'll hear all about Dr. Schultz's C-SEP approach, which focuses on using a core set of tests to identify patterns of strengths and weaknesses without overburdening students with unnecessary assessments. He emphasizes the power of achievement data and the importance of understanding the task demands of each test, challenging traditional reliance on cognitive assessments alone. Dr. Schultz also explores hot topics like the role of cognitive testing in dyslexia assessments, the debate around vision therapy, and why ensuring evaluations reflect real-world learning is key.Throughout the conversation, Dr. Schultz shares personal stories from his career, from working with students in mental health settings to developing innovative approaches to SLD identification. He stresses the importance of focusing on ecological validity, ensuring that what happens in the testing room connects to what's actually going on in the classroom. Dr. Schultz's practical advice will help LEPs, school psychologists, and educators streamline their evaluation process and make their work more impactful.This high-energy episode is packed with info and ideas for anyone looking to rethink their approach to assessments, reduce the testing burden, and truly support students' learning. If you're ready for a fresh perspective on educational evaluations, you won't want to miss this conversation. Catch Episode 38 of the Empower LEP Podcast on Spotify, Apple Podcasts, or YouTube, and be sure to subscribe, rate, and leave a review to help us reach more LEPs and educators!Connect with C-SEP:Facebook Group: https://www.facebook.com/groups/267045391029484/Connect with Empower LEP:https://empowerlep.comInstagram: https://www.instagram.com/empowerlepFacebook: https://www.facebook.com/EmpowerLEP/and the Empower LEP Facebook Group https://www.facebook.com/groups/583676341308649The website for this show is https://empowerleppodcast.com/If you enjoyed this episode, please leave a five-star rating and review on your favorite podcast platform. Your support helps us continue to bring you more inspiring stories for LEPs and supporting professionals.
Discover how industry leaders are innovating ways to give returns a second life and significantly reduce waste. This insightful panel session is moderated by Jean-Pierre Lacroix, president of SLD, with guest speakers Nancy Yousef, Chief Business Officer at Soles4Souls, and John D. Lee, President of JDL Associates. In this webinar, you will learn about:The key factors driving waste and its impact on retail performance How leading retailers are addressing this critical challenge The role of organizations like Soles4Souls in mitigating waste Six actionable strategies to transform returns and reduce waste Hosted on Acast. See acast.com/privacy for more information.
Prof. Antoni Dudek przybliża kolejne lata odradzającej się polskiej demokracji. Co działo się w polskiej polityce w połowie lat 90? W tym odcinku przypominamy m.in. początki imperium Jarosława Kaczyńskiego i upadek koalicji SLD i PSL.
Episode 277 Guest: Drew Danburry Album: I Should Have Known the Things You Never Said (Icarus Phoenix) Today I welcome back musician Drew Danburry. Drew has become one of my favorite musicians and I'm always excited when he has a new release. We discuss his latest projects, including his band Icarus Phoenix's new album I Should Have Known the Things You Never Said, set to release on August 15. Drew shares insights into his music-making process, the band's recent tour in Japan, and the inspiration behind his creative endeavors. Great chat! Thanks for listening. Kyler --- Episode Links: PURCHASE the New Album Linktree - Drew Danburry Linktree - Icarus Phoenix 2023 Interview with Drew on SLD
Probably the calmest anime Studio Trigger has ever done, it's Delicious in Dungeon on the podcast this week. We also talk about fast food, SLD knives, our most-adventurous eats and Lysol. | Follow us on Apple Podcasts | Support us on Patreon | Follow us on Twitter | Subscribe to us on YouTube | Join the fan Discord
You've heard of absence making the heart grow fonder, but for SLDs….absence makes the heart overvalue their partner, their contributions, and their abilities. SLDs or Self Love Deficients tend to have a poor self concept, rely on their partners for validation and codependently cling to their partners in regard to their emotional needs. This can result in the SLD being abandoned, which further destroys their self esteem and self worth. To avoid abandonment, the SLD may employ manipulation tactics, people please or begin fawning over their partner, which develops into overvaluation.
Episode 273 Bruce Wagner The Met Gala & Tales of Saints and Seekers --- I'm very excited to welcome back Bruce Wagner to the show. Bruce is one of my favorite writers and on this episode he shares insights into the creation of his latest work The Met Gala & Tales of Saints and Seekers. We also talk about how Arcade Publishing has begun to reissue several of his previous novels. I highly recommend them all. Links below for more information. It's always an honor to talk with with Bruce about his work. Thanks for listening. Kyler --- Episode Links: BruceWagner.la PURCHASE on Amazon SIGNED copies of The Met Gala & Tales of Saints and Seekers - available at Book Soup --- Purchase Reissues of... The Marvel Universe Dead Stars I'm Losing You A Guide for Murdered Children Force Majeure I'll Let You Go I Met Someone --- LISTEN to SLD's previous episodes with Bruce Wagner: Episode 53 - The Marvel Universe: Origin Stories Episode 84 - ROAR: American Master, The Oral Biography of Roger Orr --- SLD Podcast Info: www.saltlakedirt.com Radio Broadcast every Monday on KPCR 92.9 FM Los Gatos & 101.9FM Santa Cruz - 6PM - 8PM PST Listen on APPLE Podcasts Listen on SPOTIFY Instagram: @saltlakedirt
LDA's Education Director Dr. Monica McHale-Small talks with Dr. Nancy Mather, a Professor Emeritus of Disability and Psychoeducational Studies, about the importance of keeping the category of specific learning disabilities in the Individuals with Disabilities Education Act (IDEA) and how the SLD category could be better revised. Dr. Mather also discusses RTI as a part of the identification process for learning disabilities, how comorbidities impact an accurate learning disabilities identification, and more. Read the paper mentioned in the podcast at: https://ldaamerica.org/we-need-to-keep-but-revise-the-specific-learning-disability-construct-in-idea/
00:00:00 - Surf's Up: Season 5 Episode 19During EASL Congress 2024, US-based Roger Green, conducted interviews with Mike Betel, Louise Campbell (twice) and Sven Francque from Milano. These interviews focused on the major MASLD themes and presentations at the event. 00:04:14 - Conversation with Mike Betel beginsOn Wednesday, the first afternoon of the meeting, Mike Betel joined Roger from the convention center. The first part of the conversation centered on the Patient Advocate session that Mike chaired with Shira Zelber-Sagi. The session's goal was to discuss barriers to addressing unmet needs in a clinical setting and explore potential solutions. Mike's key takeaway: patients around the world are having challenges getting personal attention and time from their treaters. The rest of this interview touched briefly on other sessions Mike attended. 00:15:23 - First conversation with Louise Campbell Roger's first interview with Louise took place late on Thursday. She described the "really nice vibe" of the meeting, dampened by the fact that Stephen Harrison is no longer with us.The first session Louise chose to discuss was the previous day's Patient Advocate session. To her, the key point was to learn a key question that every provider should share with every patient once a year. She briefly mentioned the one presentation from the day's General Session she was able to attend: analysis of the predictive value of VCTE.00:19:53 - Philosophically important presentationsLouise discussed two sessions that delivered powerful, somewhat novel messages. The first was a symposium sponsored by Novo Nordisk about how SLD treatment could "manage the cardiometabolic side...rather than focusing on liver disease." The second was the "Healthy Livers, Healthy Lives" presentation which presented "very startling figures" about SLD impact on US healthcare costs and productivity and how and why India has targeted this disease aggressively. 00:26:29 - Building momentum and energy around AI Louise and Roger both observed that momentum is building in MASLD and mentioned why they believe this is happening, 00:33:05 - Second conversation with Louise beginsTwo days later, Louise and Roger conducted a second conversation, which focused on her enthusiasm for the updated Clinical Practice Guidelines and their practical implications. 00:36:12 - CPG session implicationsLouise said this session had "blown her mind" with its forward-thinking style and recommendations. Her favorite point? The guidelines mentioned resmetirom even before it was approved in Europe. 00:44:07 - Thoughts about medicationsRoger suggested that CPG aligned broadly with the drug presentations in the Late Breaker and General sessions. Collectively, those highlighted drugs with an array of modes of action and strengths across the metabolic continuum. 00:46:09 - Thoughts about devicesRoger asked whether Louise believed that, over time, the diagnostic focus would shift from liver stiffness and CAP to in-office PDFF. Louise discusses why this might be difficult.00:51:48 - Conversation with Sven beginsThis conversation, which took place 90 minutes after the final gavel, started with Sven praising the "vibrant hepatology community" evident at the meeting. From there, the discussion covered the Clinical Practice Guidelines, major drug development presentations and other categories. The conversation is fairly short, but packed with information and insight. 01:06:42 - Question of the WeekRoger asks what kinds of support and education primary care will need to step into a leading role in treating SLD.01:07:13 - Business ReportPlans for the next month, growth of the SurfingMASH Community, a special surprise instead of the Vault.
In this episode of All Things Policy, Anushka Saxena and Amit Kumar discuss China's Representation at the recently concluded Shangri La Dialogue 2024 in Singapore. They further talk about remarks made by Dong Jun and Cui Tiankai at the Dialogue, and the internal debate in the Chinese party-state apparatus regarding China's vision for regional security. They discuss other developments at the SLD vis-à-vis Chinese press conferences on the sidelines, and the rhetoric on Taiwan. All Things Policy is a daily podcast on public policy brought to you by the Takshashila Institution, Bengaluru. Find out more on our research and other work here: https://takshashila.org.in/ Check out our public policy courses here: https://school.takshashila.org.in/
#SLDThinkTank participant Maja Thiele, a first-time guest, shares her professional history and the traditional "one thing the audience might not know about you if you did not tell them." In the process, she talks about her professional history and a current study, LiverAIM, for which she is leading a pivotal element. Two elements make this introduction unique. First, Maja's "One Thing" answer is a first among the 120+ guests that have appeared on this podcast. She is the first SurfingMASH guest who has actually served as a radio host (old podcasters like Roger live with awe and respect for radio hosts!) Second, Jörn Schattenberg asks her to discuss her pivotal role in LiverAIM, the largest randomized control trial ever anticipated in SLD. This episode provides not only an excellent understanding of a first-time panelist we hope will join us often in the future, but also an introduction to LiverAIM, a study that will likely be the focus of many SurfingMASH episodes in years to come.
The first conversation from our #SLDThinkTank 2024 coverage explores the meeting design from two perspectives. Co-hosts Jeff Lazarus and Jörn Schattenberg discuss the overall design, after which participants Maja Thiele and Mike Betel share their reactions. The conversation starts with Jeff providing background and rationale for the #SLDThinkTank 2024 design. He starts by referring back to an initial meeting in 2019 and the first two years of INCBCN (Season 4, Episodes 13, 23; Season 3, Episodes 18, 24). He then describes why he felt a small-group brainstorming approach might work better than the last two years of PowerPoint presentations and group questions. This agenda, which was designed to encourage dialogue that generated new answers to the largest questions in SLD, included five "hot topic" sections, two focused workshops and an innovative ideation concept called Open Spaces.When Jeff finishes, Jörn describes how the highly innovative "Open Spaces" element actually worked in his section of the room.Maja and Mike share their impressions of the meeting. Maja starts by praising the Open Space concept, which she describes as "especially fruitful" due to the diversity of attendees. After Mike seconds her comment about diversity, she goes on to describe what she did during Open Spaces. The rest of the group chimes in with points about the design.
#SLDThinkTank 2024 co-chair Jörn Schattenberg and SLD Think Tank co-chair Jeff Lazarus, participants Maja Thiele and Mike Betel and SurfingMASH co-hosts Louise Campbell and Roger Green convene to discuss #SLDThinkTank, a conference designed to innovate solutions for addressing large issues, many involving public health, in conquering MASLD. 00:00:00 - Surf's Up: Season 5 Episode 15Standard lead-in, including brief quotes taken directly from the episode.00:02:45 - IntroductionOpening comments discussing the aggressive travel schedules of our guests. 00:04:02 - Meeting Maja Thiele and LiverAIMMaja introduces herself to our audience, including her "One Fact:" she has been a radio host in Denmark. Jörn mentions that Maja is about to start "the biggest randomized controlled trial in hepatology" through LiverAIM, an extremely ambitious project funded through the EU Innovative Health Initiative. 00:12:47 - GroundbreakerEach panelist shares one piece of good news from the previous week.00:15:38 - #SLD ThinkTank 2024 design Jeff provides background and rationale for the #SLDThinkTank 2024 design, going back to an initial meeting in 2019 and the first two years of INCBCN (S4, E13 and E23; S3, E18 and E 24). The event included five sections, two workshops and an innovative concept called Open Spaces. Jörn provides color about how Open Spaces actually worked. 00:20:13 - Participants' experiencesMaja praises Open Spaces, which she describes as "especially fruitful" due to the diversity of attendees. After Mike seconds this comment, she describes her Open Spaces experience. 00:25:53 - Meeting highlights Roger asks participants to describe their highlights from the meeting. Jeff describes the paper(s) that will result from this meeting, lists the ten major issues the group developed for ending the SLD pandemic, after which he elaborates on a few of these.00:29:40 - The Magic Wand exerciseJörn: at the end of the first session, chairs gave participants a "Magic Wand" to achieve their goals. He notes a consensus that "we ha[ve] mechanisms and biomarkers," but face major public and policy challenges if we are to slow the MASLD growth rate meaningfully. Maja notes the long timeline from research to implementation. 00:33:09 - Improving utilizationMike discusses prevention separate from treatment: There are only 94 FibroScan devices in Canada, and even these are underutilized. The group discusses what will be necessary to improve scanner use in a future world where having medicines motivates medical stakeholders.To Jeff, this discussion provided a sense of how the Open Space session worked and why this is the right design for big issues like "getting better bang for the buck." 00:43:59 - NIT Summit Jörn discusses the NIT Summit, which preceded the #SLDThinkTank. He sees this as a first step toward acknowledging that we need to train more people and find ways to train them better. Jeff agrees.Maya describes Elliott Tapper's state-of-the-art talk on social media. Her takeaway: video is a valuable new format, especially for younger stakeholders. 00:47:39 - Wrap-Up QuestionsRoger asks the group what other topics from #SLDThinkTank 2024 to discuss before closing. No two panelists' answers are redundant. Finally, Roger asks how non-practitioners can help drive wider awareness and action. Again, answers vary widely. 00:55:45 - Question of the WeekRoger asks listeners to describe "one way that making better use of the tools we have today (diagnostics and medicines) can make a major dent in the MASLD pandemic."00:56:38 - Business sectionThis week's news on increasing interest in SurfingMASH, our first newsletter, the Stephen Harrison Memorial page, upcoming episodes and this week's Vault.
The sudden passing on April 23 of our co-founder and colleague Stephen Harrison sent shock waves throughout the global SLD community. This week, Manal Abdelmalek and Naim Alkhouri join Jörn Schattenberg, Louise Campbell and Roger Green to remember and pay tribute to an exceptional leader, role model and human being.00:00:00 - Surf's Up: Season 5 Episode 14Episode introduction, including brief quotes taken directly from panelists. 00:03:11 - IntroductionRoger introduces the podcast. The three key opinion leaders, Jörn Schattenberg, Manal Abdelmalek and Naim Alkhouri, discuss their fast-paced, high intensity travel schedules.00:04:41 - Groundbreaker: a special memory of StephenIn place of a traditional SurfingMASH groundbreaker, Roger asks each panelist to share a special memory of Stephen. In turn, panelists discuss how they got to know Stephen and/or the role he has played in their lives. Summaries cannot do the emotion of these recollections justice.00:17:30 - One Harrison accomplishment Roger asks the group each to describe an accomplishment that Stephen has left the field. Each panelists provided at least 2 or 3, with no redundancy.00:23:52 - "Harrisonisms" and wrap-up In closing, Roger asks panelists each to provide a favorite "Harrisonism." Answers varied, although every group member recalled Stephen's question, "Is the juice worth the squeeze."00:33:33 - Question of the WeekRoger asks how listeners feel their lives or work were affected by Stephen Harrison, either directly or indirectly. 00:33:56 - Business Report This week's news on our new newsletter, future conversations, and the Vault, plus more on how we plan to honor Stephen.
This conversation starts by focusing on the impact of concomitant metabolic therapies in MASH drug development and patient treatment and then moves on to explore some major implications of the earlier conversations. Roger Green begins this conversation by returning to the issue of metabolic drugs. Specifically, he mentions a recent tirzepatide Phase 3 trial that demonstrated efficacy against symptoms of obstructive sleep apnea. Louise Campbell points out that sleep apnea correlates highly with SLD as well as obesity. She suggests this is one more point proving that we need to educate more physician specialties on liver health and educate them more effectively. Will Alazawi agrees with Louise's comment, citing a talk he and a colleague gave at the Diabetes UK conference the previous week that was part of an academic session on liver disease, noting that the session itself was well-attended. Will emphasizes applauding Diabetes UK for arranging and promoting this kind of multidisciplinary academic session of MASLD and MASH. Roger shifts focus by asking what insights investors or other professionals who listen to the episode should take from this discussion. Jörn Schattenberg starts with the most important point: we now know how to get a drug approved. Considering other drugs in development, he adds that the drugs we are studying now may be potent enough to overcome issues that challenged earlier agents. Sven Francque adds that in future years, prior use of incretin double-agonists and triple-agonists will change the nature of the MASH patient population and make drugs like Rezdiffra that have liver-specific modes of action more important and valuable.
In this conversation, Sven Francque and William Alazawi join Jörn Schattenberg, Louise Campbell, and Roger Green to review papers co-authored by Sven in 2023 and Jörn in 2020 to discuss what failure has taught us about future MASH drug development.00:00:00 - Surf's Up: Season 5 Episode 12Roger comments briefly on Stephen Harrison's passing and explains why this episode will be more sedate than usual.00:01:45 - IntroductionOpening comments from panelists.00:02:28 - GroundbreakersEach panelist shares one piece of good news from the previous week (NOTE: This was recorded before Stephen's death.)00:05:10 - Sven Francque on the State of the Graveyard in 2023Sven starts by noting how different the world is now than when he co-authored this paper in 2023. He goes on to describe three key issues in successful trials that are as relevant now as when the episode was written.00:10:59 - Efficacy endpoint challengesThe group discusses an array of challenges: that fibrosis regressions is a high bar, that patient heterogeneity presents a dilemma for trial recruitment, and that NAS score presents its own challenges. 00:18:29 - Thinking more broadly about metabolic valuesLouise suggests that in addition to stabilizing MASH, endpoints might look at related metabolic diseases that poor liver health can affect. The group considers whether placebo rates can provide guidance and reconsiders the regression and response rate issues, noting the differences between RCT patients and those in usual clinical practice. 00:28:05 - Lessons from 2020 Graveyard articleRoger asks what we have learned since 2020. Jörn points to improved consistency in reading biopsy results and greater diligence in analyzing pre-clinical data before rushing into larger late-stage trials. 00:31:49 - Implications for metabolic agents on MASH therapies Roger returns to the issue of complex drug effects, noting a recent tirzepatide Phase 3 trial on dual agonist's effect on obstructive sleep apnea. Louise notes that apnea correlates highly with SLD. Louise and Will discuss the importance of educating more physician specialties about liver health. Will discusses a presentation he made to an academic session on MASH at the Diabetes UK conference the previous week and noted that it was well-attended.00:36:05 - Looking aheadRoger asks what insights investors and others might take from this discussion. To Jörn, (i) we now know how to get a drug approved, and (ii) drugs in development today may be potent enough to overcome issues that challenged earlier agents. Sven adds that in future years, the use of incretin double-agonists and triple-agonists will change the nature of therapy. 00:42:23 - Wrap-up and closing questionLouise asks whether we are thinking broadly enough about older agents in MASH, using a recent study on low-dose aspirin (S5 - E11.) . Jörn and Roger each raise a practical challenge for such a trial. After a brief digression, Roger asks his closing question: how will having a drug approved affect the conduct of trials going forward. Answers vary and present a complex picture. you'll have to listen to learn00:51:45 - Question of the WeekThe question asks for the greatest hurdle left to overcome that will improve the percent of MASH agents achieving approval and, separately, speed approval times.00:52:14 - Back-end reportThis report includes Roger's usual weekly comment on Ukraine and Israel, followed by a tribute to Stephen Harrison. This episode was recorded the day before Stephen Harrison's untimely passing. His influence on this entire podcast was massive. Three years after he ended his co-hosting stint, there are at least two references to his research, insights, or what we called "Stephenisms" during our first anniversary episode.
Nutritionists recommend organic foods for their high mineral and phytochemical content. However, we do not pay as much attention to our daily diet as to limit it to organic foods. We need supplements to correct nutrient deficiencies. But despite their nutritional value, supplements have potential adverse health effects. My guest, Mary Esther Gilbert, has studied supplements for over 40 years and found that very few on the market are made from organically grown whole foods. Synthetic supplements lose the enzyme factor and other nutrients in the production process. Conventional supplements also lack the cofactors that the body requires to absorb plant-based nutrients. Mary also points out that some supplements have additional ingredients with potential allergenic or health-damaging effects. We need organic and whole food supplements. Mary offers the alternative of DNA drops, which are superior to nutritional supplements and contain whole food components with active enzymes to ease absorption and digestion. Tune in to learn how you can use DNA drops to detox, repair the gut, and relieve inflammation and pain. Today's Episode Explores: - How phytochemicals in plants help with elimination and detox of toxins in the body - The problems with the carnivore and low-carb diets - The issues with conventional supplements - synthetic, don't absorb, don't have the bioenergetics of plant-based nutrients - DNA Drops and how they are superior to other nutritional supplements - extraction method to retain viable healing nanoparticles from the plant cells, negative ions and submucosal delivery - HPR DNA drops for the liver detox and support - how each botanical in HPR supports the liver - How the MLS DNA drop is specifically designed to aid with gut health, which is key to successful detoxification. - My favorite DNA drop SLD to reduce inflammation and pain For more information and to learn more about DNAdrops, visit www.myersdetox.com/DNADrops After listening to this episode, you might be wondering about heavy metals. You can take my quiz here for more info: heavymetalsquiz.com About Mary Esther Miranda Gilbert: Mary Esther Miranda Gilbert, BSc NSP, MSc HN, is a nutrition science physiology and alternative medicine researcher and writer. She teaches the essential connection between understanding and applying complete and biologically correct, perpetual cellular nourishment, and mastering one's health. You can learn about her work, books, courses, and membership program at www.Holisticchoices.com. Disclaimer The Myers Detox Podcast was created and hosted by Dr. Wendy Myers. This podcast is for information purposes only. Statements and views expressed on this podcast are not medical advice. This podcast, including Wendy Myers and the producers, disclaims responsibility for any possible adverse effects from using the information contained herein. Opinions of guests are their own, and this podcast does not endorse or accept responsibility for statements made by guests. This podcast does not make any representations or warranties about guests' qualifications or credibility. Individuals on this podcast may have a direct or indirect financial interest in products or services referred to herein. If you think you have a medical problem, consult a licensed physician.
Greetings, Congregation! Thanks for finding me, and here's a short introduction to the NEW Clergy Talk. Stay tuned as we book our upcoming guest segments! Follow us: http://www.instagram.com/clergytalk Artwork by: SLD_art_comics --- Send in a voice message: https://podcasters.spotify.com/pod/show/clergy-talk/message
Outline00:00 - Intro02:40 - Classic Studies06:51 - Early Steps in Berkeley between Optimization and Circuits Theory16:04 - Back to Italy... and back to Berkeley26:29 - The SPICE program and the interaction with IBM33:30 - Logic Synthesis, Simulated Annealing, Timberwolf40:57 - The Intel x386, YACR, and ESPRESSO47:01 - The birth of Cadence and Synopsis1:06:01 - Corsi e Ricorsi in EDA1:30:45 - The Shift to Automotive and Platform-Based Design1:39:06 - OutroLinksAlberto's website: https://tinyurl.com/2w8t8fzaState-space approach in problem-solving optimization: https://tinyurl.com/bdcnmbhpEDA: https://tinyurl.com/3dur7ythSPICE: https://tinyurl.com/yxm56txyLogic Minimization Algorithms for VLSI Synthesis: https://tinyurl.com/49bnw3bySimulated annealing: https://tinyurl.com/mryz45pzTimberwolf: https://tinyurl.com/mvm28wnnIntel 386: https://tinyurl.com/4z7ubb55Cadence: https://tinyurl.com/hydjj92zSynopsis: https://tinyurl.com/463vk8mkDracula: https://tinyurl.com/kcum5v8tCorsi e ricorsi - the EDA story: https://tinyurl.com/mwar9p44G. Vico: https://tinyurl.com/cb4mp7nzFinite state machine: https://tinyurl.com/4ckszk2nSystem-level design: orthogonalization of concerns and platform-based design: https://tinyurl.com/v2t4njt4Quo Vadis, SLD? Reasoning About the Trends and Challenges of System Level Design: https://tinyurl.com/mpmmstunRemembering Richard: https://tinyurl.com/yc6rf7u3W. Shockley: https://tinyurl.com/w3chmuttSupport the showPodcast infoPodcast website: https://www.incontrolpodcast.com/Apple Podcasts: https://tinyurl.com/5n84j85jSpotify: https://tinyurl.com/4rwztj3cRSS: https://tinyurl.com/yc2fcv4yYoutube: https://tinyurl.com/bdbvhsj6Facebook: https://tinyurl.com/3z24yr43Twitter: https://twitter.com/IncontrolPInstagram: https://tinyurl.com/35cu4kr4Acknowledgments and sponsorsThis episode was supported by the National Centre of Competence in Research on «Dependable, ubiquitous automation» and the IFAC Activity fund. The podcast benefits from the help of an incredibly talented and passionate team. Special thanks to L. Seward, E. Cahard, F. Banis, F. Dörfler, J. Lygeros, ETH studio and mirrorlake . Music was composed by A New Element.
Our first conversation focusing on the new MASLD nomenclature surfaces as part of our coverage of the EASL Congress 2023. Hepatology researchers and key opinion leaders Sven Francque and Ian Rowe joined Jörn Schattenberg and Roger Green to discuss the value of the new nomenclature and its current and anticipated impact on their practices. This conversation focuses on the outcome of the nomenclature process, a three-stage Delphi process that produced new names and classifications for what had previously been known as fatty liver disease and henceforth will be known as steatotic liver disease (SLD). Sven, who was actively involved in the entire exercise, gives a concise summary of the process by which the new classifications were developed and how the new terminology will work. The rest of the conversation focuses on three issues.Excitement that we will now have the opportunity to study patients whose disease has both metabolic and alcohol-based components.The processes by which the three clinicians, Sven, Ian and Jörn are starting to share the new structure with their patients with varying degrees of success. One interesting observation emerges here from Sven: the English language terms do not translate equally into Dutch, so there is a patient advocate-led effort to create a new set of terms in Dutch.Roger raises concerns about implementation planning for the new nomenclature. One concern is around the possible impact on drug or diagnostic development and the other is about the kinds of communication issues covered in earlier episodes. Sven, who again worked more closely on the process, states with confidence that the change will not have an impact on drug or diagnostic trials. Subsequent events prove Sven right.
Venture Unlocked: The playbook for venture capital managers.
Follow me @samirkaji for my thoughts on the venture market, with a focus on the continued evolution of the VC landscape.We have a conversation with Samir Kaul from Khosla Ventures. Founded in 2004, Khosla is one of the largest and most well-known venture capital firms in the world and led by legendary investor and entrepreneur Vinod Khosla. The firm is known for investing in companies that are solving very large and complex problems. The firm currently has over $15B in AUM investing in companies such as Square, Doordash, Stripe, OpenAI, and Impossible Foods.During the episode, we covered investing across cycles, the market insanity we saw pre-2022, and how they approach both building a firm and investing. Note: We recorded this prior to the news that Keith Rabois was rejoining the firm, hence no mention of it during the discussion.About Samir Kaul:Samir Kaul is a Founding Partner and Managing Director at Khosla Ventures, and he specializes in investments across health, sustainability, food, and advanced technology sectors. His notable investments leading to successful exits through IPOs or acquisitions include companies like Vicarious Surgical, View, Guardant Health, Nutanix, Oscar, Quantumscape, Granular, SLD, NanoH2O, Iora Health, and Raxium. Additionally, he has played a pivotal role in investments in transformative startups such as Impossible Foods, Mojo Vision, Primer, and many others, demonstrating a keen eye for identifying and nurturing groundbreaking technologies and business models.Before joining Khosla Ventures, Samir's career was marked by significant achievements in biotechnology and venture capital at Flagship Ventures and the Institute for Genomic Research, where he contributed to pioneering efforts in genomics and biotech startups like Helicos BioSciences and Codon Devices. His work in sequencing the Arabidopsis genome set new standards for efficiency and impact in the field of genomics. Beyond his professional endeavors, Samir is deeply committed to philanthropy, serving on the boards of the Tipping Point Community, UCSF Benioff Children's Hospital, and the US Ski and Snowboard Association, showcasing his dedication to societal betterment and healthcare.In this episode, we discuss:(01:45) Samir's career path to venture(05:15) Traits of Successful Entrepreneurs(06:04) Building Long-term Companies(08:49) Venture Capital's Role Beyond Funding(12:13) Evolution of Venture Capital(16:15) AI and Tech Super Cycles(22:24) Learning from Past Mistakes(28:03) Investing in High Conviction Trends(32:33) Firm Culture and Decision Making(37:17) Hiring and Building a VC Team(39:12) Advice to Younger SelfI'd love to know what you took away from this conversation with Samir. Follow me @SamirKaji and give me your insights and questions with the hashtag #ventureunlocked. If you'd like to be considered as a guest or have someone you'd like to hear from (GP or LP), drop me a direct message on Twitter.Podcast Production support provided by Agent Bee This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit ventureunlocked.substack.com
Jean-Pierre Lacroix is the Founder and President of Shikatani Lacroix Design, an international design firm specializing in creating immersive experiences that connect in the blink of an eye. He is also a registered graphic designer in Ontario, a credential that demonstrates his professional standards and ethics. As a visionary leader with over three decades of experience in the branding and design industry, Jean-Pierre has helped Fortune 500 companies transform their brands and organizations through his unique “ThinkBlink” process, which combines strategic foresight, design innovation, and consumer experience engineering. He is also an accomplished speaker, author, and educator who has shared his insights and expertise on global stages, in best-selling books, and at prestigious institutions. In this episode… Building a successful retail business requires significant effort and dedication, but one crucial aspect not to overlook is the value of design. Good design is essential for creating a powerful brand identity that resonates with customers and sets you apart from competitors. Business design is a powerful tool for creating a unique brand identity, enhancing the customer experience, and driving sales. Branding and design expert Jean-Pierre Lacroix says engaging a design firm that can harness the power of strategically led design is essential for achieving design excellence. By working with experts who understand the importance of aligning design with business goals, you can be confident about your brand representation in a way that resonates with your target audience. From packaging and environmental design to graphics and digital, a skilled design team can help you deliver transformational change that drives business growth. On this episode of the Inspired Insider Podcast, Dr. Jeremy Weisz sits down with Jean-Pierre Lacroix, Founder and President of Shikatani Lacroix Design, to discuss the value of business design. Jean-Pierre explains how SLD helps its clients, the “ThinkBlink” process, the friction points SLD seeks to address, and how to remain relevant as a business.
2024 Slamdance Film Festival **THE DEATH TOUR** One of SLD's Top Picks this Year! --- Step behind the scenes of the documentary film The Death Tour. Today's episode offers a front-row seat to the passion, pain, and glory of a wrestling tour like no other. Hear directly from the creators and wrestling icons who bared their souls on screen, discussing the film's inception, the emotional bonds formed with communities, and the indomitable spirit that drives them to perform in the harshest conditions. It's a testament to the spirit of wrestling and the power of storytelling that transcends the screen. --- Synopsis: Each winter, a gang of professional wrestlers leaves Winnipeg on a wrestling trip through remote indigenous communities of Northern Manitoba. Wrestling insiders call it the “Death Tour” - both for the physical hardships endured on the road and the emotional toll it takes on those who experience it. Famous for its star-studded alumni, the trip offers wrestlers a chance to see if they have what it takes to make it in pro wrestling. The Death Tour is a meditation on the inner strength some discover when alone, exhausted and pushed to the limit. This deeply personal documentary travels through Canada's frozen North and into the wrestlers' minds as they battle the elements, each other, and the impacts of our colonial past. The wrestlers and their fans come together over their shared love of wrestling. They're both fighting for their futures and searching to heal themselves along the way. --- Episode Links: DeathTourDoc.com Film Trailer IG: @deathtourdoc --- Guests on this Episode: Stephan Peterson - Director - @stephanpetersonofficial Sonya Ballantyne - Co-Director - @sonya_ballantyne Sage Morin "The Matriarch" - @deadliestdiva Sean Dunster "Massive Damage" - @tattooed.terminator Levi Night - @levi_night
Surfing the MASH Tsunami continues its 2023 wrap-up conversations with Global Liver Institute Founder and CEO Donna Cryer, along with co-hosts Louise Campbell and Roger Green. The conversation focuses on Donna's personal health challenges in late 2023, what her absence revealed about the strength and depth of the GLI team, and what she foresees as major challenges for 2024. The conversation starts with Donna discussing a major medical event in her life during the last few months in 2024, one during which, in her words, "I almost died." She speaks briefly but clearly about the nature of the event itself, as well as how and why she is rebounding to full strength. Donna goes on to describe how well the GLI team performed in her absence and the various forms of feedback she received confirming this. In response to a question from Louise, she notes that building a strong team has always been her priority at GLI and cites several past examples where the team has led while she assumed other roles and challenges. From here, Donna notes a major change in 2023: the evolution from being a liver community to what she describes as "a community that cares about the liver," a multi-specialty, multi-stakeholder group focused on the wider implications of liver disease and patient and public health. As examples of this broader community, she cites the common guidelines from AACE and AASLD, conversations with payers and a willingness from other liver disease groups to share capabilities with the SLD community. She goes on to note that none of this change happens quickly, but that in the 10 years since GLI was formed, the scale of change has been consequential.The discussion turns toward the process of nomenclature change. Donna notes her concern throughout the process that some important implementation steps were not being considered on as timely or thorough a basis as she would have hoped. Specifically, she cites the issue of ICD codes and the need to involve primary care providers and organizations into the key processes. Louise Campbell agrees, noting the challenges around bringing wider use of VCTE into the UK system even after NICE has accepted the need to do so. Donna notes that this is the reason that GLI is calling its annual event Global Fatty Liver Day, not to be "recalcitrant, but because, as a global organization, we recognize" that not all parts of the world have adopted this nomenclature. She anticipates using what she calls "bridging documents" so that people using different nomenclatues can explain the same processes. From here, the conversation transitions to cover the growing momentum and energy in the patient and advocate communities, as evidenced by general energy and Roger's experience (along with Mike Betel) of getting pushed out of overflow rooms for patient sessions at AASLD (listen to E50.2 for more details). Finally, the conversation returns to the value of the MetALD classification, some issues around Donna's recent health scare, and a promising view of the future.
Surfing the MASH Tsunami continues its 2023 wrap-up conversations with hepatology researcher and key opinion leader Naim Alkhouri of the Arizona Liver Health Institute, along with co-hosts Louise Campbell and Roger Green. The conversation focuses on viewing the year's major events in drug development, non-invasive tests (NITs) and clinical care pathways.This conversation starts with Roger asking Naim his reaction to 2023. Naim starts by mentioning his disappointment that OCA did not get approved but shares his vision that the data presentation did not support approval and his hope and belief that resmetirom will fare better. From there, he shifts quickly to discuss being "a little bit disappointed" at the implementation of the AACE and AGA guidelines. In practical terms, he has not seen a single referral from primary care practices (PCP) for elevated FIB-4. He notes that this will require better education of PCPs, but also expresses concern that the guidelines might not be practical for them. In the effort "not to miss a single patient," he believes, authors have created a system with too many patients screened, found negative, and sent back to the PCP. Instead, he suggests, guidelines should have a more realistic goal (reducing unidentified patients from 95% to 80%) and rely on higher FIB-4 cutoffs until PCPs have integrated the concept of MASH screening into their practices. Wrapping up his view of 2023, he describes it as a "good year," although unfortunately one in which drug approval and increased pathway use did not occur.Roger suggests that the same phenomenon -- worrying more about making things perfect than making them implementable -- applied to the original rollout of the new nomenclature as well as pathways, and goes on to discuss what he sees as the behavioral psychology implications of the pathway guidelines. Naim responds with two suggestions: raise the minimum PIB-4 score at which patients are referred to 2.67 and, in the US, reflex to an ELF test before sending patients to specialists. Louise notes that ELF is not as readily available in the UK as Americans might assume. Roger adds that it might be of value to educate PCPs on the value of FIB-4 as predictive of MACE and other forms of mortality.Roger asks Naim to describe the "biggest wins" of 2023. Naim starts by citing specific advances in NITs, specifically mentioning NIS-2+ and MASEF (discussed in S4 E39). In terms of medications, he discussed the double- and triple-incretin agonists and their ability to support patients in defatting their livers and notes that, of course, resmetirom's positive Phase 3 results are the biggest story. His third item is the expansion of multi-specialty meetings that educate other specialties on SLD, why it matters, and what roles the other specialties can play in diagnosing and managing MASH patients. Roger's next question is about disappointments. Naim wishes FDA had moved further and faster in alternate drug approval pathways and metrics, but sees progress in terms of their openness to exploring NITs and, more exciting, their recently stated willingness to grant full approvals in cirrhosis based on histology. Roger asks how AI fits into the emerging picture. Naim states that AI analyses can teach a great deal about the disease, but is not practical for patient treatment. The last question: his most optimistic picture for 2024 starts with resmetirom approval, goes on to mention several exciting potential drug development results and then discusses creating MASL Centers of Excellence relying on robust NITs for diagnosis and management.
In this enlightening episode of "Well, Hello Anxiety," we are honored to be joined by Sharon Collon, an acclaimed ADHD Coach and Consultant who has dedicated her life to empowering individuals with ADHD. Sharon's passion for helping people understand the intricacies of their ADHD brains and guiding them towards creating joyful, functional lives shines through in every word she shares. Join us as we delve deep into the world of ADHD, exploring the challenges, opportunities, and strategies for thriving with this unique brain wiring. Sharon's expertise is built not just on professional knowledge but on her personal connection to ADHD, making her insights relatable and invaluable. Discover practical tips and actionable advice for making life easier with ADHD and learn how to embrace the journey towards a more joyful and fulfilling life. If you or someone you know is affected by ADHD, this episode promises to be a source of inspiration and guidance. Tune in to gain a deeper understanding of ADHD, uncover strategies for empowerment, and embark on a path towards greater well-being. Thank you for joining us for this enriching conversation with the remarkable Sharon Collon. ABOUT OUR GUEST: Meet Sharon, an accomplished ADHD Coach and Consultant who has made a significant impact in the world of ADHD awareness and support. Her mission is rooted in a deep passion for helping individuals with ADHD better understand the intricacies of their unique brain functions and guiding them towards creating joyful and functional lives. What sets Sharon apart is not just her professional expertise but her personal connection to ADHD. In her own household, ADHD is not just a topic of discussion but a shared experience, as her husband and three sons navigate the challenges of ADHD along with other conditions like Tourettes, ODD, SPD, and SLD. Sharon's journey towards becoming an ADHD advocate spans over 15 years of dedicated research and learning. She has honed her skills through rigorous training at ADDCA in New York and is recognized by the International Coaching Federation. Through her work with The Functional Family, Sharon has touched the lives of over 35,000 families, providing invaluable support and guidance. Her contributions have earned her multiple prestigious awards, including Business Awards for Outstanding Education Service, the AusMumpreneur Award for Disabled Business Excellence, and recognition in the categories of People's Choice Leadership and People's Choice Making a Difference. Sharon's commitment to her community is further underlined by her Cook's Community Award. Beyond her professional accomplishments, Sharon finds solace near the sea and treasures one-on-one moments with her sons. She also shares her life with two boxer dogs who, in her words, are more like living cartoon characters than traditional pets. Sharon's dedication to making life easier and more fulfilling for those with ADHD is nothing short of inspiring. FIND OUT MORE ABOUT THE 'WELL, HELLO SCHOOL ANXIETY' PROGRAMhttps://drjodirichardson.com/school/ ABOUT JODI: Jodi is an anxiety and well-being speaker, educator, and bestselling author. Learn more: https://drjodirichardson.com. Order Jodi's book, “Anxious Mums: How mums can turn their anxiety into strength”: https://drjodirichardson.com/product/anxious-mums/ or https://amzn.to/2YtA3ks. Order Jodi's book, coauthored with Michael Grose, “Anxious Kids: How children can turn their anxiety into resilience”: https://drjodirichardson.com/books/#order or https://amzn.to/3Bzxn3v. CONNECT WITH JODI: Connect with Jodi on LinkedIn Follow Jodi on InstagramLike Jodi's Facebook page Well, Hello Anxiety is a Postive Media Podcast. The information provided on this Podcast is for general educational purposes only, and is to be used at your sole risk. We are not liable for any reliance on this information, and it is not a substitute for professional medical advice. We recommend you seek a medical or healthcare professional if you are seeking advice, diagnosis or treatment.See omnystudio.com/listener for privacy information.
Ross Rosenberg discusses codependency/self-love deficit disorder addiction and how it fools people into believing their happiness is real. He explains how pathological narcissists exploit vulnerable codependents/SLD's by making them believe the initial false love can be brought back/rekindled."Drug Happiness" represents the codependent's belief that the Human Magnet Syndrome compelled "soulmate" experience is real and lasting. In truth, it is a temporary condition that disappears shortly after the beginning of the relationship. Pathological narcissists who are afraid of losing their SLD partner may try to re-enact the beginning of the relationship to make their partner believe in the drug happiness delusion. ABOUT ROSS ROSENBERG Ross Rosenberg, M. Ed., LCPC, CADC, is a psychotherapist, educator, expert witness, and celebrated author. He is also a global thought leader and clinical expert in codependency, trauma, pathological narcissism, narcissistic abuse, and addictions. Ross's pioneering codependency contributions are responsible for the sweeping theoretical and practical updates and developing a treatment program that permanently resolves it. Ross has been featured on national TV and radio and is a regular radio and podcast guest. In addition, he has traveled the world, giving his one-of-a-kind keynote presentations and educational workshops. His YouTube channel best illustrates his global impact with 23 million views and 260,000 subscribers and the sale of 155,000 Human Magnet Syndrome books published in 12 languages. In 2013, Ross created The Self-Love Recovery Institute, a hub for his personal development, workshops, professional training, retreats, other programs, and services.Learn more at www.SelfLoveRecovery.com. Facebook.com/TheCodependencyCure Instagram (@rossrosenberg_slri) Twitter (@RossRosenberg1) and now…TikTok! (@RossRosenberg1)ABOUT ROSS ROSENBERGRoss Rosenberg, M.Ed., LCPC, CADC is a psychotherapist, educator, expert witness, and celebrated author. He is also a global thought leader and clinical expert in codependency, trauma, pathological narcissism, narcissistic abuse, and addictions.Ross's pioneering codependency contributions are responsible for the sweeping theoretical and practical updates and developing a treatment program that permanently resolves it. Ross has been featured on national TV and radio and is a regular radio and podcast guest. In addition, he has traveled the world, giving his one-of-a-kind keynote presentations and educational workshops.His global impact is best illustrated by his YouTube channel with 23 million views and 260,000 subscribers and the sale of 155,000 Human Magnet Syndrome books published in 12 languages.In 2013, Ross created The Self-Love Recovery Institute, a hub for his personal development, workshops, professional training, retreats, other programs, and services. Learn more at www.SelfLoveRecovery.com.Facebook.com/TheCodependencyCure)Instagram (@rossrosenberg_slri)Twitter (@RossRosenberg1)and now…TikTok! (@RossRosenberg1)Support the show
Explaining codependency and self-love deficit disorder. Terri asks Ross about his "origin story." Ross also explains his redefinition of codependency to self-love deficit disorder. Ross also talks about his Observe Don't Absorb Technique (ODA) and Induced Conversation Technique. He describes what is "love bombing" as it plays out between a pathological narcissist and their prey - the self-love deficient/codependent. He explains why narcissists can't change and, because of this, why, in his Self-Love Recovery treatment program, the SLD's relationship with the narcissist always terminates. He explains the specific definition of codependency and how it has many personality variations.Support the show
The pioneer of Thermo Acoustic EnhancedUltraSound (TAEUS®), aground-breaking technology which characterizes tissue similar to an MRI, but at1/50th the costand at the point of patient care. TAEUS® is designed to work in concert with the more than 700,000ultrasound systems in use globally today. TAEUS® is initially focused on the measurementof fat in the liver as a means to assess and monitor steatotic liver disease(SLD) (formerly known as NAFLD-NASH), a chronic liver disease spectrum thataffects over two billion people globally, and for which there are no practicaldiagnostic tools. Beyond the liver, ENDRA is exploring several other clinicalapplications of TAEUS®, includingvisualization of tissue temperature during energy-based surgical procedures.
Ever wonder what these "dyslexia schools" are all about? How do you find one? Get into one? How much do they cost? And will your current district pay for them? Today our guest, Lisa Parnello of Parnello education, has all the answers for us (including outside placements that aren't for dyslexia challenges, too!) Connect with Lisa: https://ParnelloEducation.com Dyslexia Devoted Podcast: https://podcasts.apple.com/us/podcast/ep-74-the-iep-process-with-beth-from-the-iep-lab/id1628010878?i=1000633113014 Shownotes: https://TheIEPLab.com/episode151 Download your Free IEP Process Step-By-Step Guide: https://TheIEPLab.com/IEP Check out all the free resources through The IEP Lab: https://TheIEPLab.com/freeresources
Tune in for a fun-filled coffee chat with School Psych Memes, the creative genius behind the beloved and hilarious school psychology memes account. As fellow school psychologists, we discuss School Psych Memes' social media journey, work-life balance, life as a school psychologist, imposter syndrome, ADHD, SLD, testing, how to remember your endless passwords, and so much more! Get ready for laughs, insights, and relatable experiences!Make sure to check out the previous episode referenced in this episode:Episode 10: Specific Learning DisabilityEpisode LinksSchool Psychology Organization CourseSchool Psychology Forms About the Guest School Psych Memes is a dedicated professional with an impressive academic background, holding an Ed.S in school psychology achieved in 2011 and an Ed.D in school psychology earned in 2022. Currently making a positive impact in an elementary school district located in the Chicago suburbs, they have brought their expertise to support young learners' mental well-being. Originally from western Michigan, School Psych Memes has embraced the diverse experiences that shaped their journey. Beyond their professional endeavors, School Psych Memes finds joy in various hobbies. Music holds a special place in their heart, as they both listen to and play it. They cherish spending time outdoors, embracing the beauty of nature. Additionally, golf serves as a sporty outlet to unwind and stay active during their leisure hours. You can contact School Psych Memes on Instagram, TikTok, or by email at: school.psych.memes@gmail.com Subscribe to Podcast Emails here Find School Psych Finds on Instagram & TikTokFor inquiries, please email: schoolpsychfinds@gmail.com Disclaimer: This podcast offers information and education, not professional advice. It's not for legal or expert witness use. We strive for accuracy but welcome input. Your actions based on the podcast are your choice; we're not liable. Details have been altered for confidentiality. Guest opinions and third-party sites don't mirror the host's stance. Views here don't represent associated entities
Emotional Kids SummitToday Jonily Zupancic and I recap our experience at the Region 10 Summer Dyslexia Institute, Plano, TX. This event happened July 18-19, 2023. Our presentation to the General Session was on July 19th, with a breakout session for each of us after lunch. We took the time to recap our adventure and share what we talked about in this episode.You may like or dislike our approach as we continue to approach writing and math from a unique and innovative perspective. However, we both believe that changing the mindset of students with SLD comes before the actual task of writing the answers on paper. We use the acronym IMPACT to clarify our message.Join Jonily's newsletter at Jonily.comShe runs math training once per month via Zoom. Check them out.We also talk about what is happening on The Writing Glitch Podcast in August 2023.You will see an increase in episodes because the podcast is hosting The Emotional Kids Summit.If you join the Companion Course, you can also see these interviews and access over $1000 of resources for $197. Inside the Companion Course, we are offering amazing bonus materials. Some of these resources include:Complimentary call with CheriA chance to join the Math DYSConnected book launch teamAccess to The Purple X mini-courseComplimentary ticket to the Introduction to Dysgraphia WebinarComplimentary ticket to Small Group Math InterventionsComplimentary ticket to Saturday MathTwo-part on-demand webinar on dysgraphia and dyscalculia with the option to receive CEUsFree downloadable resourcesIf you join in August 2023, there is a discount.Emotional Kids Summit ★ Support this podcast ★
Shanna Diep is the CEO and founder of SLD Services. Shanna served in the USMC for 21 years active and reserve time and started SLD in 2015. SLD Services contracts tactical and medical equipment for the DOD. Website: Sldservicesllc.com Instagram: @sldservices
© 2020-2025 Ivy Podcast Discovery LLC
